Serum antibody response to BNT162b2 after natural SARS‐CoV‐2 infection

Author:

Perkmann Thomas1ORCID,Perkmann‐Nagele Nicole1,Koller Thomas1,Mucher Patrick1,Radakovics Astrid1,Wolzt Michael2,Wagner Oswald F.1,Binder Christoph J.1,Haslacher Helmuth1ORCID

Affiliation:

1. Department of Laboratory Medicine Medical University of Vienna Vienna Austria

2. Department of Clinical Pharmacology Medical University of Vienna Vienna Austria

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Reference22 articles.

1. Vaccine optimization for COVID-19: Who to vaccinate first?

2. CDC. Interim clinical considerations for use of mRNA COVID‐19 vaccines currently authorized in the United States. 2021. Accessed 2021‐02‐05.https://www.cdc.gov/vaccines/covid‐19/info‐by‐product/clinical‐considerations.html

3. Covid-19: People who have had infection might only need one dose of mRNA vaccine

4. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS‐CoV‐2 mRNA vaccine;Krammer F;medRxiv,2021

5. Single dose vaccination in healthcare workers previously infected with SARS‐CoV‐2;Saadat S;medRxiv,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3